Name | MA-0204 |
Description | MA-0204 is a highly selective and orally available peroxisome proliferator-activated receptor δ (PPARδ) modulator (EC50s: 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively). It is a potential treatment for Duchene Muscular Dystrophy (DMD). |
In vitro | MA-0204 is >10,000-fold selective for activating PPARδ over PPARα and PPARγ receptors. At concentrations of 1.2-12 nM, MA-0204 enhances fatty acid oxidation in muscle myoblasts from DMD patients in mice, shows high protein binding in mouse plasma, exhibits good permeability, and has low potential for efflux. [C.] |
In vivo | In the muscle, PPARδ (30, 100 mg/kg) enhances target gene transcription. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 40 mg/mL (83.95 mM), Sonication is recommended.
|
Keywords | PPAR | Peroxisome proliferator-activated receptors | MA-0204 | MA0204 | MA 0204 | Inhibitor | inhibit |
Inhibitors Related | PHYTOL | (S)-(+)-Ibuprofen | BADGE | Cinnamyl alcohol | Daidzein | Fenofibrate | Pioglitazone hydrochloride | 5-Aminosalicylic Acid | Naringenin | Fisetin | 2,3-Butanediol | Icariin |
Related Compound Libraries | Highly Selective Inhibitor Library | Nuclear Receptor Compound Library | Glycometabolism Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | Orally Active Compound Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Transcription Factor-Targeted Compound Library |